-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD), the leading cause of dementia, is clinically characterized by progressive memory and functional decline, pathologically characterized by neurofibrillary tau tangles originating in the medial temporal lobe and amyloidosis originating in the neocortex plaque
Alzheimer's disease (AD), the leading cause of dementia, is clinically characterized by progressive memory and functional decline, pathologically characterized by neurofibrillary tau tangles originating in the medial temporal lobe and amyloidosis originating in the neocortex plaque
The current literature on AD clinical symptom trajectories shows inconsistent results compared with DLB
In contrast to clinical diagnoses, studies based on pathologically confirmed diagnoses provide an objective gold standard for diseases and thus require a full understanding of the disease trajectories of these diseases
In addition to cognitive impairment, loss of function, especially the ability to perform self-care tasks, is a distinct feature of these degenerative disorders and is inevitably associated with a patient's dependence on family members or formal caregivers
The current retrospective longitudinal study included 62 patients with autopsy-confirmed AD alone (n=34), mixed AD+DLB (AD+DLB, n=17), and DLb alone (n=11)
The current retrospective longitudinal study included 62 patients with autopsy-confirmed AD alone (n=34), mixed AD+DLB (AD+DLB, n=17), and DLb alone (n=11)
- During a mean follow-up period of 5.
In this longitudinal study, it was found that among people with dementia, those with dementia with Lewy bodies experienced a faster rate of cognitive and functional decline than those with Alzheimer's disease alone
Source: Gu Y, Kociolek A, Fernandez KK, et al.
Clinical Trajectories at the End of Life in Dementia Patients With Alzheimer Disease and Lewy Body Neuropathologic Changes [published online ahead of print, 2022 Apr 4].
Neurology.
2022;10.
1212 /WNL.
0000000000200259.
doi:10.
1212/WNL.
0000000000200259 Gu Y, Kociolek A, Fernandez KK, et al.
Clinical Trajectories at the End of Life in Dementia Patients With Alzheimer Disease and Lewy Body Neuropathologic Changes [published online ahead of print, 2022 Apr 4].
Neurology.
2022; 10.
1212/WNL.
0000000000200259.
doi: 10.
1212/WNL.
0000000000200259
Leave a comment here
